Hindcon Chemical (HINDCON)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹22.71 |
| Market Cap | ₹116.25 Cr |
| P/E Ratio | 27.04 |
| ROCE | 9.97% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 80% |
| Debt/Equity | 0.19 |
| Sales Growth | 47.3% |
| Promoter Holding | 68.71% |
| 52-Week Range | ₹15.66 — ₹35.05 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹11.15 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹21.81, Hindcon Chemical is a small-cap specialty chemical company with a market capitalization of ₹104 crore. My first rule is never lose money, and here the earnings record raises red flags. Trailing profits have collapsed by 76.47%, and the latest quarter shows net profit of essentially zero on sales of ₹14 crore. A P/E of 35.11 means I am paying 35 years of depressed earnings for a business that is not growing. Sales have declined 6.81%. This is not a franchise with pricing power; it looks like a commodity-like chemicals supplier struggling to maintain margins. The balance sheet is not frightening: debt/equity of 0.11 is low, and ROCE of 9.97% is acceptable but not spectacular. Book value of ₹14.51 gives some support, especially at P/B of 1.50, but I prefer a margin of safety below book, not above it. Promoter holding of 68.71% is good—my interests are aligned with owners—but high holding does not compensate for deteriorating fundamentals. The Piotroski F-Score of 3 out of 9 is poor, indicating weak operating efficiency, leverage, and asset quality signals. There is no dividend, so I receive no income while waiting. I would not call this a wonderful business at a fair price; it is a struggling business at an uncertain price. As Graham said, price is what you pay, value is what you get. The value here is not evident. I need evidence of margin stabilization, positive quarterly profit, and sales growth before considering entry. Until then, this is worth watching, not buying. A possible turnaround story, but only for patient investors who accept high risk and demand concrete proof.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer